Home Business & Economics

Business & Economics

Daiichi Sankyo: Realigning for Agility

Daiichi Sankyo first approached me in 2015 with a potential opportunity in global oncology development, and I listened carefully...

Gilead Finalizes Acquisition of Immunomedics

Earlier today Foster City, California-based Gilead Sciences confirmed that it had completed the previously announced transaction to acquire Immunomedics...

Huadong Medicine and ImmunoGen Sign Strategic Agreement to Develop and Commercialize Mirvetuximab Soravtansine

ImmunoGen and Hangzhou Zhongmei Huadong Pharmaceutical Co., a wholly-owned subsidiary of Huadong Medicine Co., Chinese pharmaceutical company founded in...
Seattle Genetics

Seattle Genetics Changes Corporate Name to Seagen

Seattle Genetics confirmed that it has changed it's corporate name to Seagen. According to a statement issued by the...

Cetuximab Saratolacan Approved in Japan for the Treatment of Unresectable Locally Advanced and Recurrent...

Japan’s Ministry of Health, Labour and Welfare has approved cetuximab saratolacan sodium (previously known as RM-1929; Akalux® IV Infusion...

Merck & Co and Seattle Genetics Sign Exclusive Licensing and Co-Development Agreement

Merck & Co and Seattle Genetics have signed an exclusive licensing and co-developing agreement to globally develop and commercialize...
Scientist pipetting

Gilead Acquires Immunomedics – Accelerating an Emerging and Complementary Oncology Pipeline

Just ahead of World ADC, the industry meeting for anyone involved in the development, manufacturing antibody-drug conjugates, and the...

Creating a New Single-digit Nanogram Containment Manufacturing Facility: MilliporeSigma Announces US $65 M Investment...

In a statement today, MilliporeSigma, the Life Science business of Merck KGaA, Darmstadt, Germany, confirmed a US $65 million...

Exelixis and Catalent to Jointly Develop Multiple SMARTag®-based Antibody-drug Conjugates

Alameda- (California-) based Exelixis confirmed that it has signed a partnership agreement with Catalent to develop multiple antibody-drug conjugates...

NBE-Therapeutics and Exelixis Sign Agreement to Advance Best-in-class ADCs Against Multiple Targets

Privately-owned Swiss biotech NBE-Therapeutics and Exelixis, confirmed a new partnership to discover and develop multiple antibody-drug conjugates (ADCs) for...